XML 80 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (122,764,000) $ (101,660,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 829,000 540,000
Stock-based compensation expense 8,331,000 797,000
In-process research and development expenses 10,848,000 71,745,000
Issuance of common stock to Erasca Foundation 17,497,000  
Amortization (accretion) on investments, net 108,000 (38,000)
Change in fair value of preferred stock purchase right liability (1,615,000) (7,358,000)
Gain on remeasurement of operating lease assets and liabilities (539,000)  
Changes in operating assets and liabilities:    
Prepaid expenses and other current and long-term assets (6,711,000) (930,000)
Accounts payable 1,344,000 (380,000)
Accrued expenses and other current liabilities 11,859,000 4,693,000
Operating lease assets and liabilities, net 1,213,000 (95,000)
Net cash used in operating activities (79,600,000) (32,686,000)
Cash flows from investing activities:    
Purchases of investments (105,815,000) (99,202,000)
Maturities of investments 60,110,000 66,692,000
In-process research and development (7,680,000) (37,745,000)
Purchases of property and equipment (11,205,000) (947,000)
Net cash used in investing activities (64,590,000) (71,202,000)
Cash flows from financing activities:    
Proceeds from the issuance of common stock in initial public offering, net of discounts and issuance costs 316,999,000  
Proceeds from the issuance of convertible preferred stock, net of issuance costs 119,393,000 136,975,000
Proceeds from the exercise of stock options, net of repurchases 1,385,000 3,018,000
Proceeds from the disgorgement of stockholder's short-swing profits 553,000  
Proceeds from issuance of common stock under the Employee Stock Purchase Plan 1,067,000  
Net cash provided by financing activities 439,397,000 139,993,000
Net increase in cash, cash equivalents and restricted cash 295,207,000 36,105,000
Cash, cash equivalents and restricted cash at beginning of the period 65,688,000 29,583,000
Cash, cash equivalents and restricted cash at end of the period 360,895,000 65,688,000
Supplemental disclosure of noncash investing and financing activity:    
Issuance of common stock to Erasca Foundation 17,497,000  
Issuance of common stock in connection with asset acquisition 1,680,000  
Issuance of common stock in connection with license agreement 5,488,000  
Issuance of Series B-2 convertible preferred stock in connection with asset acquisition   30,000,000
Amounts accrued for purchases of property and equipment 3,807,000 74,000
Amounts accrued for in-process research and development expenses   4,000,000
Conversion of preferred stock to common stock upon initial public offering 340,798,000  
Vesting of early exercised options 692,000 322,000
Preferred stock purchase right liability   8,973,000
Supplemental disclosure of noncash operating activities:    
Operating lease assets obtained in exchange for lease obligation 17,498,000 $ 28,000
Tenant improvement allowance included in operating lease liabilities 16,774,000  
Reduction in operating lease assets due to lease amendment $ 1,271,000